Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (21-30 of 386) with videos related to

Pageof 39
Sort By:
Journal of Hepatology|January 8, 2004
Entecavir, FTC, L-FMAU, LdT and othersMaria Buti, Rafael Esteban
Annals of Hepatology|November 17, 2007
Long-term outcome after interferon therapy in patients with chronic hepatitis CMaria Buti, Rafael Esteban
Gastroenterology|September 30, 2015
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?Rafael Esteban, Maria Buti
Antiviral Therapy|February 22, 2021
COVID-19 and hepatitis B infectionSaleh A Alqahtani, Maria Buti
Clinics in Liver Disease|October 1, 2021
Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral TherapyMaria Buti, Mar Riveiro-Barciela, Rafael Esteban
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamideMaria Buti, Cristina Marcos-Fosch, Rafael Esteban
Alimentary Pharmacology & Therapeutics|December 19, 2019
Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' replyAdriana Palom, Mar Riveiro-Barciela, Maria Buti, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer?Mar Riveiro-Barciela, Adriana Palom, Maria Buti
Journal of Hepatology|August 25, 2015
Management of direct-acting antiviral agent failuresMaria Buti, Mar Riveiro-Barciela, Rafael Esteban
Revista Espanola De Enfermedades Digestivas|August 31, 2022
New actors come into play against hepatitis deltaMar Riveiro-Barciela, Adriana Palom, Maria Buti
Pageof 39

Showing results (21-30 of 386) with videos related to

Sort By:
Pageof 39
Journal of Hepatology|January 8, 2004
Entecavir, FTC, L-FMAU, LdT and othersMaria Buti, Rafael Esteban
Annals of Hepatology|November 17, 2007
Long-term outcome after interferon therapy in patients with chronic hepatitis CMaria Buti, Rafael Esteban
Gastroenterology|September 30, 2015
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?Rafael Esteban, Maria Buti
Antiviral Therapy|February 22, 2021
COVID-19 and hepatitis B infectionSaleh A Alqahtani, Maria Buti
Clinics in Liver Disease|October 1, 2021
Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral TherapyMaria Buti, Mar Riveiro-Barciela, Rafael Esteban
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamideMaria Buti, Cristina Marcos-Fosch, Rafael Esteban
Alimentary Pharmacology & Therapeutics|December 19, 2019
Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' replyAdriana Palom, Mar Riveiro-Barciela, Maria Buti, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer?Mar Riveiro-Barciela, Adriana Palom, Maria Buti
Journal of Hepatology|August 25, 2015
Management of direct-acting antiviral agent failuresMaria Buti, Mar Riveiro-Barciela, Rafael Esteban
Revista Espanola De Enfermedades Digestivas|August 31, 2022
New actors come into play against hepatitis deltaMar Riveiro-Barciela, Adriana Palom, Maria Buti
Pageof 39